Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
367 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,282 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07328919 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | not yet recruiting | Phase 3 | 138 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04896931 | New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC) | completed | — | 159 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| 1 |
| Jan 7, 2026 |
| clinicaltrials |
| NCT05348811 | HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | completed | Phase 2 | 25 | Zhongda HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04203160 | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | terminated | Phase 1 / Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06715839 | Target-specific immunoPET Imaging of Digestive System Carcinoma | recruiting | N/A | 400 | RenJi HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07311798 | Impact of Vascular Resection on Survival and Postoperative Outcomes in Patients With Hilar Cholangiocarcinoma: A Retrospective Study | not yet recruiting | — | 300 | Yongjun ChenOTHER | 0 | Dec 31, 2025 | clinicaltrials |
| NCT07304388 | HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC | completed | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06420349 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | terminated | Phase 1 | 7 | Mayo ClinicOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07296666 | Adjuvant Chemotherapy for BTC Based on 3D-PTA | not yet recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 0 | Dec 22, 2025 | clinicaltrials |
| NCT04400357 | Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors(PORTAL) | completed | N/A | 268 | Ruijin HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05024513 | Biliary Drainage Plus HAIC in Locally Advanced pCCA | completed | Phase 2 | 127 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291063 | Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA | recruiting | — | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | recruiting | Phase 1 / Phase 2 | 60 | Wang XinOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | terminated | Phase 2 | 10 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06416397 | Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy(PROTEOBILE) | recruiting | — | 200 | University Hospital, BordeauxOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04684862 | Infusion System for Hepatic Cancer | active not recruiting | N/A | 100 | Ronald DeMatteo, M.D.OTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07282262 | An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. | recruiting | Phase 2 | 300 | Peking Union Medical College HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06909188 | The Study of Association of Helicobacter Infections in Biliary Tract Cancers | recruiting | — | 250 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06546969 | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer | recruiting | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | active not recruiting | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | active not recruiting | Phase 2 | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07267078 | Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer | recruiting | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05921552 | Senior Adult Hepatobiliary Prehab Study | active not recruiting | N/A | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263217 | Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury | recruiting | N/A | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06440993 | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 42 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07237464 | To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants | recruiting | Phase 1 | 36 | Shenzhen Kexing Pharmaceutical Co., Ltd.NETWORK | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07153783 | Interventional AI-Human Collaboration for Liver Tumor Diagnosis | completed | N/A | 10,333 | Shengjing HospitalOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery | terminated | N/A | 41 | University of WashingtonOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT05328167 | Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment | completed | Phase 2 | 16 | Thomas Jefferson UniversityOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT07208526 | A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST | not yet recruiting | N/A | 270 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03044587 | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer(NIFE) | completed | Phase 2 | 93 | AIO-Studien-gGmbHOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05052099 | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer(COMBATBIL) | completed | Phase 1 / Phase 2 | 20 | University Hospital, EssenOTHER | 2 | Sep 29, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT06358001 | EchoTip AcuCore Post-Market Clinical Study | completed | — | 183 | Cook Research IncorporatedINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06731998 | Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery(LapTAP) | recruiting | N/A | 48 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07176962 | A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening | recruiting | — | 1,800 | Yingbin Liu, MD, PhD, FACSOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06893380 | Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer(GENTIS) | recruiting | — | 61 | CHA UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07169916 | Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer(YJ-BTC) | not yet recruiting | N/A | 210 | Fudan UniversityOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06123117 | STALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy(STALL) | recruiting | N/A | 850 | Helsinki University Central HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2026source: clinicaltrials